JESSICA RIVERA: Open Payments
NPI 1437598588 · CLEMSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,758 in 105 payments from 26 companies in 2025. Trend: 2023 $1,980 · 2024 $1,449 · 2025 $1,758
Food & beverage: $1,758
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $496 |
| Teva Pharmaceuticals USA, Inc. | 14 | $231 |
| Neurocrine BioSciences, Inc. | 5 | $103 |
| AstraZeneca Pharmaceuticals LP | 5 | $69 |
| Lundbeck LLC | 4 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| Neurelis, Inc. | 3 | $62 |
| Novo Nordisk Inc | 3 | $61 |
| Lilly USA, LLC | 4 | $57 |
| ARGENX US, INC. | 2 | $54 |
Products named: AUSTEDO XR, VRAYLAR, UBRELVY, INGREZZA, CAPLYTA, VALTOCO, QULIPTA, VYVGART HYTRULO.
Industry payments across SC — which companies pay providers there.
